Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Spruce Biosciences's share price for the quarter that ended in Mar. 2024 was $0.7859. Spruce Biosciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 41.15 Mil. Therefore, Spruce Biosciences's market cap for the quarter that ended in Mar. 2024 was $32.34 Mil.
Spruce Biosciences's quarterly market cap
increased
from Sep. 2023 ($92.01 Mil) to Dec. 2023 ($120.22 Mil) but then
declined
from Dec. 2023 ($120.22 Mil) to Mar. 2024 ($32.34 Mil).
Spruce Biosciences's annual market cap
declined
from Dec. 2021 ($104.77 Mil) to Dec. 2022 ($25.90 Mil) but then
increased
from Dec. 2022 ($25.90 Mil) to Dec. 2023 ($120.22 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Spruce Biosciences's Enterprise Value for Today is $-46.14 Mil.
Spruce Biosciences Market Cap Historical Data
The historical data trend for Spruce Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spruce Biosciences's Market Cap
For the Biotechnology subindustry, Spruce Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spruce Biosciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's Market Cap falls into.
Spruce Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Spruce Biosciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences (NAS:SPRB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Spruce Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Spruce Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Spruce Biosciences (Spruce Biosciences) Business Description
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPRB has been successfully added to your 